CLDX250117C28000
- 1.24
- 0.000.00%
Celldex Therapeutics Newsroom
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
Celldex Therapeutics Analyst Ratings
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
Celldex Therapeutics Analyst Ratings
Cantor Fitzgerald Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67
TD Cowen Maintains Celldex Therapeutics(CLDX.US) With Buy Rating
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $44 to $80
Celldex Therapeutics Analyst Ratings
Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $90
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $44 to $78
Goldman Sachs Maintains Celldex Therapeutics(CLDX.US) With Hold Rating, Maintains Target Price $45
Citi Initiates Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $70
Celldex (CLDX) Gets a Buy From Citi
Celldex Therapeutics Analyst Ratings
Celldex Therapeutics Initiated at Neutral by Goldman Sachs
Goldman Sachs Initiates Celldex Therapeutics(CLDX.US) With Hold Rating, Announces Target Price $45
Hold Rating on Celldex Therapeutics Amid Drug Development Prospects and Competitive Challenges
TD Cowen Maintains Celldex Therapeutics(CLDX.US) With Buy Rating